JP6478916B2 - 薬物耐性乳癌の予後判定および処置のための治療アジュバントおよびバイオマーカーとしてのｍｉＲＮＡ - Google Patents

薬物耐性乳癌の予後判定および処置のための治療アジュバントおよびバイオマーカーとしてのｍｉＲＮＡ Download PDF

Info

Publication number
JP6478916B2
JP6478916B2 JP2015542832A JP2015542832A JP6478916B2 JP 6478916 B2 JP6478916 B2 JP 6478916B2 JP 2015542832 A JP2015542832 A JP 2015542832A JP 2015542832 A JP2015542832 A JP 2015542832A JP 6478916 B2 JP6478916 B2 JP 6478916B2
Authority
JP
Japan
Prior art keywords
mir
hsa
mirna
cells
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015542832A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502527A (ja
JP2016502527A5 (enExample
Inventor
マンジート ケイ． ラオ
マンジート ケイ． ラオ
ジャフェール エス． イマーム
ジャフェール エス． イマーム
ベハール ゾヒ
ベハール ゾヒ
ヤオ‐フ チャン
ヤオ‐フ チャン
パネードス スバラヤル
パネードス スバラヤル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2016502527A publication Critical patent/JP2016502527A/ja
Publication of JP2016502527A5 publication Critical patent/JP2016502527A5/ja
Application granted granted Critical
Publication of JP6478916B2 publication Critical patent/JP6478916B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015542832A 2012-11-16 2013-11-15 薬物耐性乳癌の予後判定および処置のための治療アジュバントおよびバイオマーカーとしてのｍｉＲＮＡ Expired - Fee Related JP6478916B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727481P 2012-11-16 2012-11-16
US61/727,481 2012-11-16
PCT/US2013/070350 WO2014078686A1 (en) 2012-11-16 2013-11-15 Mirnas as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers

Publications (3)

Publication Number Publication Date
JP2016502527A JP2016502527A (ja) 2016-01-28
JP2016502527A5 JP2016502527A5 (enExample) 2016-12-28
JP6478916B2 true JP6478916B2 (ja) 2019-03-06

Family

ID=50731724

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542832A Expired - Fee Related JP6478916B2 (ja) 2012-11-16 2013-11-15 薬物耐性乳癌の予後判定および処置のための治療アジュバントおよびバイオマーカーとしてのｍｉＲＮＡ

Country Status (6)

Country Link
US (2) US9730954B2 (enExample)
EP (1) EP2919817A4 (enExample)
JP (1) JP6478916B2 (enExample)
CN (1) CN104884097B (enExample)
CA (1) CA2930795A1 (enExample)
WO (1) WO2014078686A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263135B1 (en) 2015-02-25 2020-01-15 Bioneer Corporation Pharmaceutical composition for treating cancer comprising microrna as active ingredient
CN106148538B (zh) * 2016-08-09 2019-10-22 山东大学 microRNA标志物组及其在制备评价乳腺癌化疗敏感性试剂盒中的应用
CN107970254A (zh) * 2017-12-08 2018-05-01 新乡医学院第附属医院 miR-204及其靶基因在诊断和治疗骨肉瘤中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016548A2 (en) * 2005-08-01 2007-02-08 The Ohio State University Research Foundation Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
CN102007408A (zh) * 2008-02-28 2011-04-06 俄亥俄州立大学研究基金会 与急性髓性白血病(aml)中的细胞遗传学和预后相关的微rna特征及其用途
CN102076853A (zh) * 2008-05-07 2011-05-25 阿布拉西斯生物科学有限责任公司 通过miRNA增强药物疗法
EP2354246A1 (en) * 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer

Also Published As

Publication number Publication date
CN104884097B (zh) 2018-11-06
JP2016502527A (ja) 2016-01-28
CN104884097A (zh) 2015-09-02
US9730954B2 (en) 2017-08-15
EP2919817A4 (en) 2016-10-19
US20180177815A1 (en) 2018-06-28
EP2919817A1 (en) 2015-09-23
US10617709B2 (en) 2020-04-14
US20150306127A1 (en) 2015-10-29
WO2014078686A1 (en) 2014-05-22
CA2930795A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
Kamerkar et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Yan et al. Delivery of anti-microRNA-21 by lung-targeted liposomes for pulmonary fibrosis treatment
CN102510719B (zh) 用与细胞毒性化学治疗剂组合的内皮素受体抑制剂治疗脑转移
US10406128B2 (en) Treatment and diagnosis of colon cancer
Blumental-Perry et al. Retrograde signaling by a mtDNA-encoded non-coding RNA preserves mitochondrial bioenergetics
Sun et al. RETRACTED: MicroRNA-146-5p promotes proliferation, migration and invasion in lung cancer cells by targeting claudin-12
WO2015133522A1 (ja) 大腸癌の治療剤、及び大腸癌患者の予後の予測方法
US20220280590A1 (en) Use of inhibitors of yap and sox2 for the treatment of cancer
US12565650B2 (en) STAUFEN1 regulating agents and associated methods
Suresh et al. AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma
US10617709B2 (en) miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers
CN114786683A (zh) 一种siRNA、药物组合物以及使用其治疗糖尿病的方法
JP2023512449A (ja) Ｔａｐ６３制御された発がん性長鎖非コードｒｎａ
US20250283078A1 (en) Rna compositions and therapeutic methods thereof
WO2016107933A2 (en) Materials and methods for the treatment of cancers
TW201932123A (zh) 包含微小rna及其衍生物作為活性成分之藥物組成物
US20180303863A1 (en) Pharmaceutical Composition for Treating STK11-Mutation Cancer Using Cardiac Glycosides
JP7804918B2 (ja) ｓｉＲＮＡ、ＤＮＡ、ベクター、女性がん細胞増殖抑制剤、女性がんの腫瘍形成抑制剤、医薬、及び長鎖非コードＲＮＡの利用
WO2026096962A1 (en) Methods and compounds for treating, ameliorating and/or preventing fibrotic diseases
Tian et al. LncRNA LLNLR-299G3. 1 promotes ESCC progression by regulating cancer related genes through RNA-chromatin interactions
CN120393010A (zh) AhR-HEGBC-CYP1A1调控轴在制备抗胆囊癌药物中的应用
US10561679B2 (en) Double-stranded nucleic acid molecule, DNA, vector, cancer cell growth inhibitor, cancer cell migration inhibitor, and drug
EP4499827A1 (en) Micrornas for inhibiting the expression of trf2 in tumors
CA2680058C (en) Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity
BRPI1012325B1 (pt) Vetor viral para uso no tratamento e/ou na prevenção de tumores, método diagnóstico in vitro para avaliar o estágio histopatológico tumoral e a presença de metástases, bem como kit de diagnóstico in vitro

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190205

R150 Certificate of patent or registration of utility model

Ref document number: 6478916

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees